Announced details
Mild cognitive impairment (MCI) due to Alzheimer’s disease and mild dementia, collectively referred to as early Alzheimer’s disease, as an initial treatment
Average administration time of 15 seconds per injection. Weekly subcutaneous administration was confirmed to provide exposure equivalent to intravenous administration once every 2 weeks.
Eisai estimates that the number of people with early Alzheimer’s disease in China was 17 million in 2024. Leqembi was launched in China in June 2024.
Eisai and Biogen jointly commercialize and co-promote lecanemab. Eisai leads global development and regulatory submissions, and will market the product and provide information in China.
China’s pharmaceutical regulatory authority. Other information, including location, representative, capital and year of establishment, is not disclosed.
The impact on the forecast for the fiscal year ending March 2027 is expected to be immaterial, and there is no change to the earnings forecast announced on 15 May 2026.
The company does not address Contract Value / Offering price.
The Clarity AD trial, long-term extension (LTE) study, subcutaneous administration substudy, and modeling and simulation. Market and patient numbers are Eisai estimates.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Leqembi® (generic name: lecanemab) subcutaneous formulation, “Leqembi” auto-injector (SC-AI) |
| Counterparty | China's National Medical Products Administration (NMPA) |
| Counterparty overview | China’s pharmaceutical regulatory authority. Other information, including location, representative, capital and year of establishment, is not disclosed. |
| Relationship with the Company | Eisai and Biogen jointly commercialize and co-promote lecanemab. Eisai leads global development and regulatory submissions, and will market the product and provide information in China. |
| Launch date | During FY2026 (scheduled) |
| Applicable area | Mild cognitive impairment (MCI) due to Alzheimer’s disease and mild dementia, collectively referred to as early Alzheimer’s disease, as an initial treatment |
| Quantitative Effects | Average administration time of 15 seconds per injection. Weekly subcutaneous administration was confirmed to provide exposure equivalent to intravenous administration once every 2 weeks. |
| Usage history | Eisai estimates that the number of people with early Alzheimer’s disease in China was 17 million in 2024. Leqembi was launched in China in June 2024. |
| Impact on Business Performance | The impact on the forecast for the fiscal year ending March 2027 is expected to be immaterial, and there is no change to the earnings forecast announced on 15 May 2026. |
| Source | The Clarity AD trial, long-term extension (LTE) study, subcutaneous administration substudy, and modeling and simulation. Market and patient numbers are Eisai estimates. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The product received approval from China’s National Medical Products Administration (NMPA). Eisai explained that subcutaneous administration is expected to shorten administration time and enable treatment at home, reducing the burden of hospital visits, providing greater flexibility in treatment options, and improving the efficiency of healthcare resources.